Christian Blank, from Netherlands Cancer Institute, and colleagues conducted this two-arm Phase 1b trial consisting of 18 high-risk stage III B/C melanoma patients who had palpable nodes; the median number of lymph nodes involved was 2 (range, 1-4) and 1 (range, 1-5) in the respective arms. The objective response rate (ORR) was 78%. So far, none of the responding patients within the neoadjuvant arm has relapsed.
Ipilimumab plus Nivolumab Adjuvant in Stage 3 Melanoma has a high response rate but comes with considerable side effects (more and more severe side effects in Stage 3 than Stage 4 patients). So Stage 3 Melanoma respond BETTER but have MORE side effects; immune system seems to be suppressed in Stage 4. LBA39 Opacin trial'' Note by Bettina Ryll
More about this research here (posted by Gilly in MPNE forum).